MoonLake Immunotherapeutics (MEX:MLTXN) FCF Yield %: -13.41 (As of Jun. 26, 2026)


MEX:MLTXN MoonLake Immunotherapeutics MEX:MLTXN
30 GF Score
Price MXN305.30
! 3 Warning Signs
View Full Analysis

What is MoonLake Immunotherapeutics FCF Yield %?

MoonLake Immunotherapeutics MEX:MLTXN 30 FCF Yield % is -13.41 as of Jun. 26, 2026. GuruFocus rates MEX:MLTXN with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,418 Biotechnology companies, MoonLake Immunotherapeutics ranks worse than 60.44% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, MoonLake Immunotherapeutics's Trailing 12-Month Free Cash Flow is MXN-4,100.64 Mil, and Market Cap is MXN29,477.41 Mil. Therefore, MoonLake Immunotherapeutics's FCF Yield % for today is -13.41%.

The historical rank and industry rank for MoonLake Immunotherapeutics's FCF Yield % or its related term are showing as below:

MEX:MLTXN' s FCF Yield % Range Over the Past 10 Years
Min: -13.41   Med: 0   Max: 0
Current: -13.41

MEX:MLTXN's FCF Yield % is ranked worse than
60.44% of 1418 companies
in the Biotechnology industry
Industry Median: -9.715 vs MEX:MLTXN: -13.41

MoonLake Immunotherapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

MoonLake Immunotherapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

MoonLake Immunotherapeutics FCF Yield % Related Terms

MoonLake Immunotherapeutics FCF Yield % Historical Data

* Premium members only.

The historical data trend for MoonLake Immunotherapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MoonLake Immunotherapeutics FCF Yield % Chart

MoonLake Immunotherapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
0.00 0.00 -1.61 -3.60 -4.60

MoonLake Immunotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.58 -6.02 -4.78 -5.52 -21.71

MEX:MLTXN vs AVBP, BCAX, KALV: FCF Yield % Comparison

For the Biotechnology subindustry, MoonLake Immunotherapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MoonLake Immunotherapeutics FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's FCF Yield % falls into.


MEX:MLTXN
30GF Score
MoonLake Immunotherapeutics MEX:MLTXN
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MoonLake Immunotherapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

MoonLake Immunotherapeutics's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-3529.873 / 76669.9508
=-4.60%

MoonLake Immunotherapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-1195.316 * 4 / 22022.5102
=-21.71%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -13.41 mean?
MoonLake Immunotherapeutics (MEX:MLTXN) has a FCF Yield % of -13.41 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MoonLake Immunotherapeutics and its competitors. According to the industry distribution chart, MoonLake Immunotherapeutics ranks #857 out of 1418 companies in the Biotechnology industry, placing it in the top 60.4%.
Is MoonLake Immunotherapeutics' FCF Yield % too high?
MoonLake Immunotherapeutics' current FCF Yield % is -13.41. Based on the distribution chart, MoonLake Immunotherapeutics ranks #857 out of 1418 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MoonLake Immunotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' FCF Yield % compare to AVBP and BCAX?
According to the Biotechnology industry distribution chart, MoonLake Immunotherapeutics ranks #857 out of 1418 companies for FCF Yield %. This places MoonLake Immunotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MoonLake Immunotherapeutics and its competitors. MoonLake Immunotherapeutics's current FCF Yield % is -13.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MEX:MLTXN) has a current FCF Yield % of -13.41. The current FCF Yield % is -13.41. MoonLake Immunotherapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MEX:MLTXN), the current FCF Yield % is -13.41 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MoonLake Immunotherapeutics Business Description

Other Exchanges MLTX:USA
Address Dorfstrasse 29, Zug, CHE, 6300
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
30GF Score

Get the complete analysis for MEX:MLTXN

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN305.30
Price